Pluripotent stem cell derived cardiac cells for myocardial repair

Wuqiang Zhu, Ling Gao, Jianyi Zhang

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Human induced pluripotent stem cells (hiPSCs) must be fully differentiated into specific cell types before administration, but conventional protocols for differentiating hiPSCs into cardiomyocytes (hiPSC-CMs), endothelial cells (hiPSC-ECs), and smooth muscle cells (SMCs) are often limited by low yield, purity, and/or poor phenotypic stability. Here, we present novel protocols for generating hiPSC-CMs, -ECs, and -SMCs that are substantially more efficient than conventional methods, as well as a method for combining cell injection with a cytokine-containing patch created over the site of administration. The patch improves both the retention of the injected cells, by sealing the needle track to prevent the cells from being squeezed out of the myocardium, and cell survival, by releasing insulin-like growth factor (IGF) over an extended period. In a swine model of myocardial ischemia-reperfusion injury, the rate of engraftment was more than two-fold greater when the cells were administered with the cytokine-containing patch comparing to the cells without patch, and treatment with both the cells and the patch, but not with the cells alone, was associated with significant improvements in cardiac function and infarct size.

Original languageEnglish (US)
Article numbere55142
JournalJournal of Visualized Experiments
Issue number120
StatePublished - Feb 3 2017


  • Cell therapy
  • Developmental biology
  • Heart
  • Heart failure
  • Infarct
  • Issue 120
  • Myocardium
  • Pluripotent stem cells

ASJC Scopus subject areas

  • Neuroscience(all)
  • Chemical Engineering(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)


Dive into the research topics of 'Pluripotent stem cell derived cardiac cells for myocardial repair'. Together they form a unique fingerprint.

Cite this